Andrew R Allen
CIK 1374539 · PRESIDENT AND CEO · last filed 2026-06-18
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
CLVS price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SUITE 200
BOULDER, CO 80301
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CGEM | Director | — | $14.68 | — | $0 | 2 | 2026-06-18 |
| Adaptimmune Therapeutics PLC (ADAP) Delisted | Director | — | $0.06 | — | $0 | 3 | 2024-07-01 |
| Gritstone bio, Inc. (GRTS) Delisted | PRESIDENT AND CEO | 1,310,360 | $0.03 | $42.2K | -$18.2K | 9 | 2024-06-26 |
| TCR2 THERAPEUTICS INC. (TCRR) Delisted | Director | — | $1.48 | — | $0 | 6 | 2023-06-01 |
| Sierra Oncology, Inc. (SRRA) Delisted | Director | 0 | $54.99 | $0 | $108.2K | 7 | 2022-07-01 |
| Epizyme, Inc. (EPZM) Delisted | Director | 20,560 | $1.47 | $30.2K | $0 | 8 | 2021-06-15 |
| Clovis Oncology, Inc. (CLVS) Delisted | See Remarks | 192,519 | $0.08 | $15.6K | -$12.02M | 8 | 2015-03-04 |
| PHARMION CORP (PHRM) Delisted | Chief Medical Officer, EVP | 40,200 | — | — | $0 | 4 | 2007-12-07 |
Recent Filings · Page 2 of 5
48 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-12-19 | TCR2 THERAPEUTICS INC. (TCRR) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-07-01 | Sierra Oncology, Inc. (SRRA) Delisted | Disp (D) | −1,650 | -$90.8K | EDGAR |
| 2022-04-20 | Gritstone bio, Inc. (GRTS) Delisted | Grant (A) | +70,000 | $0 | EDGAR |
| 2021-12-10 | TCR2 THERAPEUTICS INC. (TCRR) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-11-19 | Gritstone bio, Inc. (GRTS) Delisted | Grant (A) | +48,200 | $0 | EDGAR |
| 2021-06-15 | Epizyme, Inc. (EPZM) Delisted | Grant (A) | +8,060 | $0 | EDGAR |
| 2021-06-09 | Sierra Oncology, Inc. (SRRA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-03-10 | Gritstone bio, Inc. (GRTS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-12-11 | TCR2 THERAPEUTICS INC. (TCRR) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-06-10 | Sierra Oncology, Inc. (SRRA) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.